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Summary 
Complement activation may predispose to vascular 
injury and atherogenesis. The atheroprotective 
actions of unidirectional laminar shear stress led us 
to explore its influence on endothelial cell 
expression of complement inhibitory proteins 
CD59 and decay-accelerating factor. Human 
umbilical vein and aortic endothelial cells were 
exposed to laminar shear stress (12 dynes/cm2), or 
disturbed flow (+/-5 dynes/cm2 at 1Hz), in a 
parallel-plate flow chamber. Laminar shear 
induced a flow rate-dependent increase in steady-
state CD59 mRNA, reaching 4-fold at 12 
dynes/cm2. Following 24-48 hours of laminar shear 
stress, cell surface expression of CD59 was 
upregulated by 100%, while decay-accelerating 
factor expression was unchanged. The increase in 
CD59 following laminar shear was functionally 
significant, reducing C9 deposition and 
complement-mediated lysis of flow-conditioned 
endothelial cells by 50%. While CD59 induction 
was independent of PI-3K, ERK1/2 and nitric 
oxide, an RNA interference approach 
demonstrated dependence upon an ERK5/KLF2 
signalling pathway. In contrast to laminar shear 
stress, disturbed flow failed to induce endothelial 
cell CD59 protein expression. Likewise, CD59 
expression on vascular endothelium was 
significantly higher in atheroresistant regions of 
the murine aorta exposed to unidirectional laminar 
shear stress, when compared to atheroprone areas 
exposed to disturbed flow. We propose that 
upregulation of CD59 via ERK5/KLF2 activation 
leads to endothelial resistance to complement-
mediated injury, and protects from atherogenesis in 
regions of laminar shear stress. 
 
Introduction 
The complement cascade provides an essential 
defence against bacterial infection and a bridge 
between innate and adaptive immunity (1). 
However, by the nature of its cytolytic activity, 
complement has the potential to inflict injury on 
bystander host tissues including vascular 
endothelium. C1q, C3a, C5a and the C5b-9 
membrane attack complex (MAC)2 have the 
capacity to exert pro-inflammatory effects on 
vascular endothelial cells (EC) including induction 
of cellular adhesion molecules and cytokine 
secretion, increased leukocyte adhesion and 
generation of a pro-thrombotic endothelial surface 
(2-5).  Mechanisms implicated in complement 
deposition on the surface of EC include activation 
of the classical pathway by immune complexes, 
anti-phospholipid and anti-endothelial cell Abs (6), 
and through recognition of apoptotic cell blebs by 
the globular head of C1q (7). Alternatively, 
activation of the lectin pathway may follow 
exposure to hypoxia-reoxygenation (8). 
 
Complement activation on the surface of human 
EC is regulated by membrane-bound inhibitory 
proteins: decay-accelerating factor (DAF) (CD55), 
membrane cofactor protein (MCP, CD46) and 
CD59. The genes encoding DAF and MCP are 
clustered on the long arm of chromosome 1, while 
that for CD59 is located on chromosome 11. These 
proteins use distinct mechanisms for complement 
regulation. DAF prevents the formation and 
accelerates the decay of C3 and C5 convertases (9), 
while MCP accelerates the degradation of C3b and 
C4b by Factor I (10). CD59 inhibits the terminal 
pathway of complement activation, preventing 
incorporation of C9 into the MAC (11,12).  
 
Complement activation may be an early pre-
lesional event in atherogenesis, as revealed by 
colocalisation of C5b-9 with lipid deposits in the 
tunica intima prior to monocyte recruitment (13). 
Experimental models suggest that vascular 
endothelial injury is the earliest detectable event in 
atherogenesis. Apoptosis of EC occurs 
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preferentially at bifurcations and curvatures, where 
denudation of vascular endothelium enhances the 
risk of plaque development and local thrombosis. 
Moreover, aging and exposure to oxidized low-
density lipoprotein (ox-LDL), or reactive oxygen 
species, increases EC apoptosis, consistent with a 
role in the initiation of atherogenesis (14). In 
addition to local lipid-related activation of 
complement, exposure of the underlying 
extracellular matrix, resulting from apoptosis of 
EC, may further reinforce complement activation 
(13,15).  
 
The susceptibility of branch points and curvatures 
to atherosclerosis is in large part related to 
exposure to disturbed blood flow (DF), with low 
shear reversing or oscillatory flow patterns. In 
contrast, the arterial tree exposed to unidirectional 
laminar shear stress (LSS) >10 dynes/cm2 tends to 
be protected (16). This is reflected in the 
phenotype of EC exposed to LSS, typically 
characterized by enhanced nitric oxide (NO) 
biosynthesis, prolonged cell survival and an 
anticoagulant, anti-adhesive cell surface (17-19). 
In contrast, endothelium exposed to DF exhibits 
reduced levels of eNOS, increased apoptosis, 
generation of reactive oxygen species, 
permeability to LDL and leukocyte adhesion 
(reviewed in (16)).  
 
The importance of unidirectional LSS for vascular 
endothelial cytoprotection, together with the 
observation that LSS protects against complement-
induced EC activation and chemokine synthesis 
(20), led us to explore whether LSS may be 
protective against complement-mediated vascular 
injury through suppression of the C5b-9 membrane 
attack complex. We show for the first time that 
CD59, the predominant membrane-bound regulator 
of the MAC, is preferentially induced by 
unidirectional atheroprotective LSS, providing 
enhanced protection against complement activation. 
This response was independent of NO and 
dependent upon an ERK5, Kruppel-like Factor2 
(KLF2) signalling pathway. In contrast, an 
atheroprone disturbed flow waveform failed to 
increase CD59 protein expression. These 
observations were confirmed in vivo, where CD59 
expression was significantly higher on arterial EC 
in atherosclerosis-resistant areas of the murine 
aorta. Thus, upregulation of CD59 may represent 
an important component of endothelial 
cytoprotection in regions of LSS, preserving 
vascular integrity and minimizing both 
complement activation and atherogenesis. 
 
Experimental procedures 
Materials 
Anti-human CD59 mAb (IgG1) Bric 229 was 
purchased from the International Blood Group 
Reference Laboratory (Bristol, UK). The anti-
murine CD59 mAb (MEL-4) was a gift from BP 
Morgan (University of Wales School of Medicine). 
Anti-DAF monoclonal antibody (mAb) 1H4 (IgG1) 
and anti-MCP mAb TRA-2-10 (IgG1) were gifts 
from D. Lublin and J. Atkinson respectively 
(Washington University School of Medicine, St 
Louis, Mo). UO126 and NG-monomethyl-L-
arginine (L-NMMA) were from BIOMOL 
(Plymouth Meeting, PA) and LY290042 from 
Merck Biosciences (Nottingham, UK). Other 
products were from Sigma-Aldrich (Poole, UK).  
 
Endothelial cell exposure to flow 
Human umbilical vein ECs (HUVEC) and human 
aortic ECs (HAEC; purchased from Promocell, 
Heidelberg, Germany), were cultured as described 
(21). The use of human EC was approved by 
Hammersmith Hospitals Research Ethics 
Committee (ref no. 06/Q0406/21). Confluent 
HUVEC or HAEC cultures were exposed to 
control static conditions, high shear unidirectional 
laminar flow (up to 20 dynes/cm2), or disturbed 
flow with directional changes of flow at 1Hz (+/- 5 
dynes/cm2), for up to 48h using a parallel-plate 
flow chamber (Cytodyne, La Jolla, CA, USA) as 
described previously (22,23). Cell viability was 
assessed by examination of EC monolayers using 
phase contrast microscopy, cell counting and 
estimation of trypan blue exclusion. 
 
RNAi design and transfection 
The short interfering RNA (siRNA) duplexes were 
from Dharmacon Inc. (Lafayette, CO) or Ambion 
(Austin, TX). siRNA sequences for KLF2: (Sense: 
5’-GCCCUACCACUGCAACUGGUU-3’), 
(Antisense: 5’-
CCAGUUGCAGUGGUAGGGCUU-3’), siRNA 
sequences for ERK5: (Sense: 5’-
GGCUCGGCUUGGUUAAUUCtt-3’), 
(Antisense:5’-GAAUAAUCCAAGCCGAGCCtc-
3’). Corresponding negative control sequences 
were commercially synthesized. For siRNA 
delivery, HUVECs were plated at 3 x 105 cells per 
well on fibronectin-coated glass slides in 
Endothelial Cell Basal Media (EBM2) (Cambrex 
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BioScience Wokingham, UK) to obtain 50% 
confluency. siRNA targeting KLF2, ERK5 or 
scrambled control siRNA (all at 10-50nM) was 
transfected into EC using oligofectamine-based 
transfection in EBM2 media. EC were cultured for 
48h in EBM2 and analysed for target gene 
expression by qRT-PCR or immunoblotting. The 
specificity of siRNA targeting was confirmed 
using a second set of sequences. 
 
Quantitative real-time (RT)-PCR  
Quantitative RT-PCR was performed using an 
iCycler (BioRad, Hercules, CA) as described 
(24,25). β-actin, GAPDH and HPRT were used as 
housekeeping genes, with data calculated in 
relation to β-actin and verifed with GAPDH and 
HPRT. DNase-1-digested total RNA (1 μg) was 
reverse transcribed using 1μM oligo-dT and 
Superscript reverse transcriptase (Invitrogen, 
Paisley, UK), according to the manufacturers 
instructions. cDNA was amplified in a 25 μl 
reaction containing 5 μl cDNA template, 12.5 μl 
iSYBR supermix (BioRad), and 0.5pM sense and 
antisense gene-specific primers and ddH2O. Primer 
sequences used were: β-actin forward 5’-
GAGCTACGAGCTGCCTGACG-3’, β-actin 
reverse 5’-
GTAGTTTCGTGGATGCCACAGGACT-3’; 
KLF2 forward 5’-
CTTTCGCCAGCCCGTGCCGCG-3’, KLF2 
reverse 5’- AAGTCCAGCACGCTGTTGAGG-3’; 
CD59 forward 5’-ATGCGTGTCTCATTAC-3’, 
CD59 reverse 5’-TTCTCTGATAAGGATGTC-3’; 
ERK5 forward 5’-
AGTACGAGATCATCGAGACC-3’; ERK5 
reverse 5’-CTCCCTGAGGGTCCGCTTGG-3’.  
 
Northern blotting 
RNA was extracted from HUVEC using the 
RNeasy kit Qiagen Ltd (Crawley, UK). Total RNA 
was separated on a 1% agarose/formaldehyde gel, 
transferred overnight to Hybond-N nylon 
membranes (Amersham Biosciences) and analysed 
by specific hybridization to a radiolabeled cDNA 
probe for human CD59 (gift from H Waldmann, 
University of Oxford, UK) as previously described 
(26). Integrated density values for each band were 
obtained with an Alpha Innotech ChemiImager 5500 
Alpha Innotech (San Leandro, CA), normalised with 
respect to the 28S band on ethidium bromide-
stained rRNA loading patterns and expressed as 
percent change from control.  
Flow cytometry 
Flow-cytometry was performed as previously 
described using a Beckman-Coulter flow cytometer 
(Luton, UK) (26). The results are expressed as the 
relative fluorescent intensity (RFI), representing 
mean fluorescent intensity (MFI) with test mAb 
divided by the MFI using an isotype-matched 
irrelevant mAb.  
 
Complement deposition assays 
Cell surface C9 deposition and complement-
mediated lysis was assessed by flow-cytometry as 
described previously (24). EC were exposed to 
LSS at 12 dynes/cm2 for 24h, harvested and 
suspended in veronal buffered saline containing 
0.1% gelatin (VBSG). The non-complement fixing, 
inhibitory CD59 mAb BRIC 229 (27) was used at 
20 µg/ml. For analysis of C9 deposition, EC were 
exposed to normal human serum (NHS) or heat-
inactivated NHS (HIHS) for up to 3h at 37oC. C9 
binding was detected with mouse anti-human C5b-
C9 Technoclone (Vienna, Austria) and FITC-
rabbit-anti-mouse Ig. Complement-mediated cell 
lysis was quantified by assessing the percentage of 
cells permeable to propidium iodide (PI), by flow-
cytometry, following exposure to NHS or HIHS 
for 3h.  
 
Confocal microscopy  
Confocal immunostaining and microscopy was by 
modification of an established method (28). 
C57BL/6 mice (8 weeks) were killed by CO2 
inhalation, and the vasculature perfused-fixed with 
1% paraformaldehyde in PBS. Thoracic organs 
were removed en bloc and equilibrated in OCT for 
18 hours. The aortic arch was dissected and a 
transverse slice cut, which encompassed the 
circumference of the aorta at the origin of the 
brachiocephalic trunk, the brachiocephalic trunk 
itself and the proximal portions of its branches 
(right common carotid and right subclavian). The 
block was frozen in isopentane and serial cryostat 
sections cut and incubated with 10% normal goat 
serum (Dako, Ely, UK), followed by rat anti-
mouse CD59 mAb MEL-4 for 30 mins. Sections 
were washed and incubated with 1:200 goat-anti-
rat-AlexaFluor 568 (Molecular Probes, Invitrogen, 
Paisley, UK). Sections used for quantitation were 
stained only for CD59. Adjacent sections were 
immunolabelled with anti-CD59 as before, and 
then incubated with biotinylated Griffonia 
simplicifolia isolectin B4 (Vector Laboratories, 
Burlingame, CA), followed by steptavidin-
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AlexaFluor-488 (Invitrogen). Other serial sections 
were immunolabelled with anti-CD59, followed by 
AlexaFluor 488, then incubated with Cy3-labelled 
mouse monoclonal anti-smooth muscle actin 
(clone α-1A4, Sigma). After the second label, 
sections were washed in PBS and incubated for 10 
min with TOPRO-3 (Molecular Probes) and 
mounted in PBS/glycerol.  
 
Sections were examined with a Zeiss LSM 510 
Meta inverted confocal microscope (Thornwood, 
NY). Scan and photomultiplier (PMT) settings 
were set to optimize signal/noise ratio for each 
emission wavelength. Using these PMT settings, 
there was no detectable crossover between 
channels. However, to eliminate any possibility of 
data skew by signal contamination, quantitation 
was performed on CD59-only stained sections. 
Processing was with Zeiss LSM Image Browser 
and quantitation by export of the images into 
Image J. The regions of interest were selected and 
the histogram function used to calculate the 
distribution of pixel intensities on the red channel 
(corresponding to AlexaFluor 568).  
 
Animals 
C57BL/6 mice were purchased from Harlan Olac 
(Bicester, Oxford, UK) and housed under 
controlled climactic conditions in microisolator 
cages with autoclaved bedding. Irradiated food and 
drinking water were readily available. All animals 
were housed and studied according to UK Home 
Office guidelines. Sentinel mice were housed 
alongside test animals and regularly screened for a 
standard panel of murine pathogens. 
 
Statistics 
Data are expressed as the mean of individual 
experiments ± standard error of the mean (SEM). 
Data were grouped according to treatment and 
analyzed using GraphPad Prism software (San 
Diego, CA) and the analysis of variance with 
Bonferroni correction or an unpaired Students t-
test. Kolmogorov-Smirnov analysis was used to 
compare immunofluorescence intensity in different 
regions of the murine aorta using an Excel plug-in 
Stat-Plus Professional. Differences were 
considered significant at P values of <0.05. 
 
Results 
CD59 expression is induced by unidirectional LSS 
To assess the influence of shear stress on the 
surface expression of the complement inhibitory 
proteins MCP, DAF and CD59, HUVEC in a 
parallel-plate flow chamber were exposed to 
unidirectional LSS (12 dynes/cm2) for up to 48h 
and analyzed by flow cytometry. No change in the 
cell surface expression of either MCP or DAF was 
seen (Figure 1). In contrast, a significant increase 
in CD59 expression of up to 2.5-fold was seen  
following exposure to unidirectional LSS for 24h 
and this was sustained at 48h (Figure 1).     
 
Northern analysis detected alternatively spliced 
variants of CD59 (as described previously (24)) 
and demonstrated that induction by LSS was 
associated with an increase in mRNA, first 
detectable 2h post the onset of flow and continuing 
to rise over 16h. This pattern was confirmed by 
qRT-PCR, which revealed a sustained increase of 
up to 6-fold, 24-48h post-initiation of LSS (Figure 
2). To determine whether LSS-induced 
upregulation was dependent upon the magnitude of 
shear force, HUVEC were exposed to increasing 
LSS for 24h and changes in CD59 mRNA 
analyzed by qRT-PCR. CD59 mRNA levels rose 
progressively as LSS increased to 12 dynes/cm2 
(Fig 2C).   
 
Experiments performed on HAEC, to represent EC 
derived from a vascular bed affected by 
atherosclerosis, also showed a significant 
upregulation of CD59 mRNA and cell surface 
protein in response to LSS (Figure 3). The 
extracellular matrix upon which EC are cultured 
may also influence their responsiveness to shear 
stress (29). To address this, HUVEC were cultured 
on fibronectin, gelatin and collagen type I and 
exposed to LSS for 24h. However, the nature of 
the underlying matrix did not alter the ability of 
LSS to induce CD59, with equivalent induction 
seen under all conditions (data not shown). 
 
LSS-induced CD59 is cytoprotective 
To address the functional significance of CD59 
upregulation, the effect of LSS on cell surface 
deposition of C9 was measured. HUVEC were 
cultured under static conditions or in the presence of 
LSS (12 dynes/cm2) for 24h prior to exposure to 
20% normal human serum (NHS) and flow-
cytometric analysis, using an antibody against a 
neo-epitope on C9 that is revealed upon C5b-9 
complex formation. In addition, complement-
mediated EC lysis was quantified using propidium 
iodide uptake (24). Exposure to NHS resulted in 
measurable C9 deposition on the surface of 
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HUVEC cultured under static conditions. A 
significant reduction in C9 deposition was seen on 
EC exposed to LSS (p<0.05), with levels 
comparable to that seen on EC exposed to serum 
that had been heat-inactivated to prevent 
complement activation (Figure 4A). Likewise, LSS 
conferred protection against complement-mediated 
lysis, when compared to EC cultured under static 
conditions (p<0.05) (Figure 4B). The inhibitory, 
non-complement fixing CD59 mAb BRIC 229 (27) 
was used to confirm the role of CD59 in protection 
against lysis. BRIC 229 reversed the protective 
effect of LSS and its presence resulted in lysis of 
>75% of EC (Figure 4B).     
 
Mechanosensitive signalling pathways regulating 
expression of CD59 
Activation of signaling pathways such as those 
regulated by PI-3K/Akt and ERK1/2, and 
enhanced eNOS-dependent NO biosynthesis, may 
contribute to the vasculoprotective effects of LSS 
(30).  Thus, we initially adopted a pharmacological 
approach to explore the role of these pathways in 
the induction of CD59 by LSS. HUVEC were pre-
treated with PI-3K antagonist LY290042, or MEK-
1 inhibitor UO126, at concentrations we have 
shown to inhibit phosphorylation of Akt and 
ERK1/2 respectively (31,32). Inclusion of 
LY290042 had no significant inhibitory effect on 
the induction of CD59 mRNA in response to LSS 
(Figure 5A). Although UO126 reduced expression, 
this did not reach significance (Figure 5B). 
Likewise, the presence of nitric oxide synthase 
inhibitor L-NMMA, at concentrations capable of 
inhibiting the induction of CD59 by atorvastatin 
under hypoxic conditions (24), did not inhibit LSS-
induced CD59 protein (Figure 5C) or mRNA 
expression (not shown).  
 
In contrast, inclusion of the protein synthesis 
inhibitor cycloheximide abrogated the LSS-
mediated increase in CD59 mRNA (Figure 5D), 
suggesting dependence upon de novo synthesis of 
an inducible intermediary protein in response to 
LSS. Furthermore, it has been reported that in 
addition to MEK-1, UO126 may inhibit ERK5 (33), 
hence the decrease in flow-induced CD59 mRNA 
observed in the presence of UO126 (Figure 5B) 
may in fact reflect a reduction in ERK5 activation. 
These data, combined with (i) the identification of 
ERK5 (BMK-1) as a shear-inducible 
cytoprotective member of the MAPK family (34), 
(ii) identification of the LSS-inducible 
transcription factor KLF2 as a downstream target 
of ERK5 (35,36), and (iii) microarray data 
suggesting over-expression of KLF2 may increase 
CD59 mRNA in EC (36), led us to investigate the 
role of ERK5/KLF2 further. The KLFs are a 
subclass of the zinc-finger transcription factors, 
within which KLF2 has emerged as an important 
factor in the maintenance of endothelial 
homeostasis (37,38). We adopted an siRNA 
approach, which reduced the expression of ERK5 
transcripts in EC by 80% (Supplementary Figure 
1A). Further analysis demonstrated that the 
induction of both CD59 mRNA (Supplementary 
Figure 2A) and surface protein by LSS was 
significantly attenuated in HUVEC treated with 
ERK5 siRNA, when compared to scrambled 
siRNA controls (p<0.01) (Figure 6A).  
 
LSS significantly induced expression of KLF2 
mRNA, a response that was reversed by the 
presence of specific siRNA oligonucleotides 
targeting KLF2 (Supplementary Figure 1B). In 
addition, knockdown of ERK5 significantly 
inhibited induction of KLF2 by LSS 
(Supplementary Figure 1C). Analysis of CD59 
mRNA in HUVEC pretreated with KLF2-specific 
siRNA, demonstrated that LSS induction of CD59 
was inhibited, an effect that was not seen with 
scrambled control siRNA (Supplementary Figure 
2B). This was further confirmed by flow-
cytometric analysis, which showed that cell surface 
expression of CD59 on EC treated with KLF2 
siRNA and exposed to LSS was equivalent to that 
on static cells (Figure 6B). 
 
CD59 expression is differentially regulated by LSS 
and DF 
Atheroprotected and atheroprone regions of the 
aorta are exposed to unidirectional LSS and a low 
velocity reversing flow pattern respectively. To 
compare the effect of these different flow patterns 
on CD59 expression, EC were exposed to LSS (12 
dynes/cm2), or an oscillatory flow pattern (±5 
dynes/cm2 at 1 Hz) to model DF. Changes in 
endothelial cell morphology and CD59 expression 
were compared with cells cultured under static 
conditions. Preliminary experiments performed to 
validate the model, demonstrated characteristic 
morphological changes in response to LSS (Figure 
7A) and induction of intercellular adhesion 
molecule-1 (ICAM-1) by LSS and vascular cell 
adhesion molecule-1 (VCAM-1) by DF 
respectively (22) (Supplementary Figure 3). 
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Furthermore, while LSS induced KLF2 mRNA 
expression, no such response was seen in EC 
exposed to DF (Supplementary Figure 3C). In 
subsequent experiments, a 4.3-fold increase in 
CD59 mRNA above static levels was seen 
following 24h LSS. In contrast, CD59 mRNA 
induction was reduced to 2-fold in EC exposed to 
DF, significantly lower than LSS (p<0.05) (not 
shown). Likewise, LSS induced a significant 
increase in EC surface CD59 expression when 
compared to static cultured EC (p<0.01), while no 
change was seen in response to DF (Figure 7B). 
  
CD59 expression is differentially expressed in the 
murine aorta 
A murine model was used to explore further the in 
vitro observation of differential regulation of 
CD59 by unidirectional LSS and DF. Regions of 
murine aorta exposed to LSS and DF can be 
determined by geometry, with straight portions 
exposed to LSS and the inner curve of the aortic 
arch and the aortobrachiocephalic junction exposed 
to DF (39). Murine aortae were perfused-fixed, 
sectioned longitudinally and analyzed by 
immunohistochemistry for CD59 expression. As 
seen in Figure 8 A-C, CD59 expression was 
greater on vascular endothelium in areas of the 
aorta and brachiocephalic artery (not shown) 
predicted to be exposed to atheroprotective LSS, 
when compared to the inner curve of the aorta and 
the aortobrachiocephalic branch point, exposed to 
DF. To confirm the presence of intact endothelium 
at the DF sites, sections were stained with 
Griffonia simplicifolia isolectin B4 (Figure 8C). 
Similar analysis demonstrated intact EC at LSS 
sites (not shown). Quantification of endothelial 
CD59 expression at multiple sites within LSS and 
DF exposed areas of the aorta confirmed a 
significant difference (Figure 8D). These results 
demonstrate differential expression of CD59, the 
most potent regulator of the MAC, with specific 
reduction on endothelium in atheroprone sites of 
the aorta. 
  
Discussion 
The data presented herein suggest that LSS 
enhances vascular endothelial resistance to 
complement-mediated injury through induction of 
CD59 expression. Vascular wall injury contributes 
to the initiation of atherogenesis, a complex 
multifactorial inflammatory disease process 
propagated by both local and systemic factors. 
Activation of the classical or alternative 
complement pathways (40-42) may be involved in 
the pathogenesis of atherosclerosis from the pre-
lesional stage (13), through early arterial wall 
lesions (43) and intermediate and advanced 
plaques (44), via generation of C3a, C5a and the 
C5b-9 MAC. LSS is an essential component of 
vascular endothelial homeostasis, contributing to 
resistance against apoptosis and the maintenance 
of an anti-proliferative, anti-oxidant, anti-
thrombotic, anti-adhesive endothelial barrier 
(reviewed in (45)). Although LSS-dependent 
induction of eNOS and NO biosynthesis is an 
important regulator of many of these mechanisms 
(17), the cytoprotective effects of LSS remain to be 
fully elucidated.  
 
CD59 is a glycosylphosphatidylinositol-anchored, 
18-25 kDa molecule, belonging to the Ly-6 
superfamily of cell surface proteins (11,12). 
Through its ability to bind to the α-γ-subunit of C8, 
CD59 prevents the incorporation of C9 into C5b-9 
(46). Thus CD59, which is constitutively expressed 
on the vascular endothelial surface, is the 
predominant membrane-bound regulator of the 
MAC. In light of the role of complement activation 
in atherogenesis and of LSS in atheroprotection, 
we explored the effect of shear stress on 
endothelial cell CD59 expression. We have shown 
that 24-48h of atheroprotective LSS enhances 
CD59 protein expression in HUVEC and HAEC 
and that this response is attenuated in EC exposed 
to an oscillatory flow pattern (±5 dynes/cm2 at 1 
Hz), modelling disturbed flow characteristic of 
atheroprone regions of the vasculature. 
Comparison of the level of CD59 expression at 
sites of the murine aorta exposed to LSS and DF 
supported the relevance of these observations to 
the in vivo situation. Moreover, the enhanced 
expression of CD59 in response to LSS resulted in 
increased endothelial resistance to C5b-9 
deposition and complement-mediated injury. 
 
Urbich and colleagues demonstrated an increase in 
EC clusterin in response to LSS and, as we show 
for CD59, this response was independent of 
enhanced NO synthesis (20). Of note, they did not 
detect a change in CD59 protein expression, which 
may reflect differences in experimental conditions 
including the time courses used. Urbich analyzed 
CD59 protein expression following 18h of LSS, 
whereas we first saw a significant increase in 
protein expression at 24h. Clusterin, a 
multifunctional cytoprotective molecule, acts to 
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inhibit complement-mediated cytolysis by binding 
to C5b-6 and preventing formation of the MAC. 
Thus, increased expression of both soluble 
(clusterin) and membrane-bound (CD59) inhibitors 
of the MAC may contribute significantly to the 
atheroprotective actions of LSS through reduction 
of complement-mediated EC activation and injury. 
Of these, CD59 is considered to be the most potent 
endothelial regulator of the MAC. In contrast DF, 
in addition to reducing protection against 
complement, may in fact increase complement 
activation by enhancing alternative pathway 
activity through induction of endothelial properdin 
synthesis. EC synthesis of properdin, a stabilizer of 
C3 and C5 convertases, is a significant contributor 
to plasma levels and is markedly enhanced 
following exposure of EC to DF (47). 
 
KLF2 is one of 17 KLFs, a subclass of the zinc-
finger transcription factors. KLF2 is flow inducible 
and differentially expressed in areas of the aorta 
exposed to LSS and DF (48). KLF2 activity has 
emerged as an important regulator of endothelial 
cytoprotective genes including eNOS, 
thrombomodulin and heme oxygenase-1, which 
exert anti-inflammatory, anti-thrombotic and anti-
oxidant effects (25,36-38). An ERK5/myocyte 
enhancing factor 2 pathway regulating KLF2 
transcription has been identified (35,36). Thus, 
KLF2 represents an important transcriptional 
effector in the cytoprotective actions of LSS (38). 
We have now added induction of CD59 and 
protection against complement-mediated injury to 
the atheroprotective profile of shear stress, a 
response which mirrors the effect of LSS and DF 
on KLF2 expression. Using siRNA we have 
demonstrated that CD59 induction by LSS is 
dependent-upon ERK5 and KLF2 activity. In 
support of a role for KLF2, microarray analysis 
revealed a 2.65-fold increase in CD59 mRNA 
following adenoviral over-expression of KLF2 in 
HUVEC for 24h (36). In contrast, lentiviral over-
expression of KLF2 for 7 days failed to detect a 
change in CD59 mRNA, while showing a 1.98-
fold induction of DAF (38). Thus, further studies 
are required to delineate the regulation and 
outcomes of KLF2 pathway activity, including its 
relationship to upstream mechanotransducers and 
signaling mediators and with downstream target 
gene promoters. Analysis of the 5kb region 
upstream of the CD59 gene transcription start site 
revealed potential KLF2 5’-CACCC-3’ binding 
sites. Detailed examination of the CD59 promoter 
and definition of the precise relationship with 
KLF2 are beyond the scope of the current 
manuscript, and will be addressed in future studies.   
 
Complement activation is tightly controlled so as 
to avoid host injury. While lysis of nucleated cells 
is rare, sub-lytic C5b-9 may induce tissue factor 
expression and release of soluble factors from EC 
and VSMC including platelet-derived growth 
factor, IL-1, IL-6 and MCP-1 (49-51). The 
resultant proliferation of EC and VSMC, combined 
with induction of cellular adhesion molecules, 
monocyte chemotaxis, EC apoptosis and 
thrombosis may contribute to atherogenesis. Hence, 
maintenance of cell surface CD59 to limit C5b-9 
deposition is essential. We propose that in areas of 
the vasculature where this is insufficient, such as 
sites exposed to DF, a threshold is exceeded 
whereby levels of C5b-9 deposition are reached 
that induce EC injury with pro-inflammatory, pro-
atherogenic sequelae. A concept supported by our 
recent report of increased atherosclerosis in 
CD59/LDL receptor-deficient mice (S Yun, VWY 
Leung, M Botto, JJ Boyle, DO Haskard: submitted 
for publication). Moreover, our observation that 
the induction of cell-surface CD59 expression by 
LSS is significantly reduced by the 
immunosuppressive drug cyclosporine A (CsA) 
(data not shown), suggests this may be a 
contributory factor in CsA-mediated vasculopathy.   
  
A further indication of the importance of CD59 in 
vasculoprotection comes from the study of 
diabetes mellitus (DM). EC protection mediated by 
CD59 may be compromised in DM by two 
mechanisms; glycation of CD59 leading to loss of 
function (52) and hyperglycemic-induced shedding 
of cell surface protein (53). Dysfunctional glycated 
CD59 is detectable in the urine of patients with 
DM, and colocalises with the increased MAC 
deposited on the vascular endothelium of target 
tissues (54). The consequent release of growth 
factors and the pro-inflammatory, pro-thrombotic 
sequelae in the vasculature may be a significant 
factor in the accelerated atherogenesis associated 
with DM.  
 
In conclusion, our data reveal induction of the 
complement-inhibitory protein CD59 to be a novel 
cytoprotective outcome of LSS-induced activation 
of the ERK5/KLF2 signaling pathway. The 
demonstration of differential regulation of CD59 
by LSS and DF suggests CD59 expression may be 
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a contributory factor in the protection afforded by 
LSS against atherogenesis. Through the inhibition 
of the terminal MAC, CD59 has the potential to 
exert anti-inflammatory and vasculoprotective 
effects. Moreover, data demonstrating that HMG-
CoA reductase antagonists activate KLF2 
(25,55,56) and enhance CD59 expression (24), 
suggest that modulation of KLF2 represents an 
important component of the vasculoprotective 
profile of statins and emphasizes the therapeutic 
potential of KLF2-related signalling pathways. 
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Footnotes 
 
1ARK and FA contributed equally to this study. 
 
2The abbreviations used are: MAC, membrane attack complex; EC, endothelial cells; DAF, decay-
accelerating factor; ERK, extracellular signal-regulated kinase; KLF2, Kruppel-like Factor2; Ox-LDL, 
oxidized low-density lipoprotein; LSS, laminar shear stress; DF, disturbed flow; NO, nitric oxide; C; PI-3K, 
phosphoinositide-3 kinase; L-NMMA, NG-Monomethyl-L-arginine; HUVEC, human umbilical vein 
endothelial cells; HAEC, human aortic endothelial cells; Quantitative real-time-polymerase chain reaction, 
qRT-PCR; RFI, relative fluorescent intensity; MFI, mean fluorescent intensity; FBS, fetal bovine serum; 
VBSG; veronal buffered saline containing 0.1% gelatin; NHS, normal human serum; HIHS, heat-
inactivated NHS; PI, propidium iodide; ICAM-1, intercellular adhesion molecule-1; VCAM-1, vascular 
cell adhesion molecule-1; SEM, standard error of the mean. 
 
This work was funded by Arthritis Research Campaign Fellowships to ARK (KO566) and JCM (13616). 
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Figure legends 
 
Figure 1. CD59 expression is upregulated by prolonged laminar shear stress. HUVEC were exposed 
to unidirectional laminar shear stress (LSS) 12 dynes/cm2 or cultured under static conditions for up to 48h 
after which DAF, MCP and CD59 expression were determined by flow-cytometry. Data are expressed as 
mean relative fluorescence intensity (RFI) ± SEM from three experiments.*p<0.05. 
 
Figure 2 CD59 induction is dependent upon the magnitude of shear force  
A and B. HUVEC were exposed to LSS for up to 48h and CD59 mRNA quantified by A. northern 
blotting (with fold change calculated by densitometric quantification of 3 separate experiments) and B. 
real-time quantitative PCR (qRT-PCR). C. HUVEC were exposed to varying LSS (0-12 dynes/cm2) for 
24h and CD59 mRNA quantified by qRT-PCR. Data expressed as mean ± SEM from 2-5 
experiments.*p<0.05 **p<0.01, ***p<0.001. 
 
Figure 3. HAEC CD59 expression is upregulated by prolonged LSS. HAEC were exposed to LSS (12 
dynes/cm2) or cultured under static conditions for 24h prior to quantification of A. CD59 mRNA by qRT-
PCR and B. CD59 surface protein by flow-cytometry. Data expressed as mean ± SEM from three 
experiments. *p<0.05. 
 
Figure 4. LSS enhances EC resistance to complement-mediated lysis. HUVEC were exposed to LSS 
(12 dynes/cm2) (grey bars) or cultured under static conditions for 24h (black bars). EC were then left 
untreated (UT) or exposed to 20% normal human serum (NHS) or heat-inactivated serum (HIHS) for up to 
3h. A. C9 deposition was measured by flow-cytometry using an antibody against a neo-epitope on C9 that 
is revealed upon C5b-9 complex formation. B. Percentage EC lysis was calculated as the number of 
propidium iodide positive cells expressed as a percentage of total cells. CD59 activity was inhibited by 
pre-treatment with mAb Bric 229. Data expressed as mean RFI ± SEM from 3 experiments. *p<0.05. 
  
Figure 5. Induction of CD59 by LSS is independent of PI-3K, ERK1/2 and NO. HUVEC were 
exposed to LSS (12 dynes/cm2) or cultured under static conditions for 24h in the presence of A. 
LY290042 (20μM) B. U0126 (5μM), C. L-NMMA (100μM) and D. Cycloheximide (3μg/ml) or vehicle 
control. CD59 mRNA was quantified by qRT-PCR and EC surface CD59 expression by flow-cytometry. 
Values are normalized and shown as the increase in CD59 expression above constitutive levels on 
untreated EC cultured under static conditions. Data expressed as mean ± SEM from three experiments. 
*p<0.05 **p<0.01. 
 
Figure 6. Induction of CD59 by LSS is dependent upon ERK5 and KLF2. HUVEC were left 
untransfected (UT) or transfected with scrambled control siRNA (Scr) or ERK5-specific siRNA (A), or 
KLF2 siRNA (B), prior to exposure to LSS (12 dynes/cm2) or culture under static conditions for 24h. Cell 
surface CD59 expression was analysed by flow-cytometry. Data expressed as mean ± SEM from 3 
experiments. *p<0.05. 
 
Figure 7. CD59 is differentially regulated by laminar and disturbed flow. HUVEC were exposed to 
static culture, LSS (12 dynes/cm2) or disturbed flow (DF) (1Hz, +/- 5 dynes/cm2) for 24h. A. Phase-
contrast photomicrographs demonstrating EC monolayer morphology, the arrow shows the direction of 
LSS. B. EC surface CD59 expression was quantified by flow-cytometry. Data expressed as mean ± SEM 
from three experiments. *p<0.05 **p<0.01. 
 
Figure 8. Analysis of CD59 expression in the murine aorta. Murine aortae were analyzed by 
immunohistochemistry and laser-scanning confocal microscopy. Endothelial CD59 expression (red) 
indicated by arrows in regions of the aorta exposed to A. laminar flow and B. low shear disturbed flow at 
the inner arch of the aorta. C. inner arch of the aorta stained with Griffonia simplicifolia (EC marker, red), 
CD59 (bright green), elastin (dull green), Topro (nuclear dye, blue).  D. Image analysis quantification 
demonstrating maximal CD59 expression on EC in areas of the aorta exposed to LSS and reduced CD59 
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on EC at the inner curve of the aorta (predicted disturbed flow), n = 3 mice (*p<0.001, Kolmogorov-
Smirnov analysis). Scale bars = 50 μm. 
